Wall Street analyst estimates for Sanofi (SNY): consensus price target and buy/hold/sell recommendations.
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 12 |
| Hold | 14 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 27 |
| Avg rating (−2 sell to +2 buy) | 0.41 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-04 | $1.07 | ||
| 2026-10-30 | $2.04 | $1.56 | +30.8% |
| 2026-07-30 | $1.21 | $1.10 | +10.0% |
| 2026-04-23 | $1.10 | $1.06 | +3.8% |
| 2026-01-29 | $0.89 | $0.84 | +6.0% |
| 2025-10-24 | $1.70 | $1.60 | +6.2% |
| 2025-07-31 | $0.90 | $0.96 | -6.2% |
| 2025-04-24 | $0.94 | $0.90 | +4.4% |
Valuation Ratios
| P/E Ratio | 24.39 |
| Price / Book | 1.38 |
| EV / EBITDA | 8.07 |
| Dividend Yield | 10.45% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 34.70B EUR | 36.22B EUR | 35.68B EUR | 37.63B EUR | 37.37B EUR | 39.17B EUR | 40.56B EUR | 41.62B EUR | 44.29B EUR | 46.72B EUR |
| Cost of Revenue | 10.70B EUR | 11.61B EUR | 11.44B EUR | 11.98B EUR | 12.16B EUR | 12.26B EUR | 11.88B EUR | 12.63B EUR | 13.21B EUR | 13.05B EUR |
| Gross Profit | 24.00B EUR | 24.61B EUR | 24.24B EUR | 25.65B EUR | 25.21B EUR | 26.92B EUR | 28.68B EUR | 28.99B EUR | 31.08B EUR | 33.67B EUR |
| Research & Development | 5.17B EUR | 5.47B EUR | 5.89B EUR | 6.02B EUR | 5.53B EUR | 5.69B EUR | 6.50B EUR | 6.51B EUR | 7.39B EUR | 7.84B EUR |
| Selling, General & Admin | 9.48B EUR | 10.07B EUR | 9.86B EUR | 9.88B EUR | 9.39B EUR | 9.55B EUR | 8.74B EUR | 8.93B EUR | 9.18B EUR | 10.24B EUR |
| Operating Expenses | 17.46B EUR | 18.80B EUR | 19.57B EUR | 22.60B EUR | 11.10B EUR | 18.79B EUR | 18.52B EUR | 22.03B EUR | 23.83B EUR | 24.07B EUR |
| Operating Income | 6.53B EUR | 5.80B EUR | 4.68B EUR | 3.05B EUR | 14.11B EUR | 8.13B EUR | 10.16B EUR | 6.96B EUR | 7.25B EUR | 9.60B EUR |
| EBITDA | 9.90B EUR | 9.64B EUR | 9.18B EUR | 10.66B EUR | 17.53B EUR | 11.54B EUR | 13.51B EUR | 11.39B EUR | 11.03B EUR | 12.48B EUR |
| Interest Expense | 399.5M EUR | 333.4M EUR | 486.5M EUR | 536.3M EUR | 430.8M EUR | 377.4M EUR | 384.8M EUR | 512.8M EUR | 622.6M EUR | 626.0M EUR |
| Pre-tax Income | 5.81B EUR | 5.62B EUR | 4.90B EUR | 3.01B EUR | 14.14B EUR | 7.84B EUR | 9.99B EUR | 6.12B EUR | 6.76B EUR | 6.02B EUR |
| Income Tax | 1.32B EUR | 1.72B EUR | 481.0M EUR | 121.0M EUR | 1.81B EUR | 1.56B EUR | 1.91B EUR | 1.02B EUR | 1.20B EUR | 1.04B EUR |
| Net Income | 4.71B EUR | 8.42B EUR | 4.31B EUR | 2.75B EUR | 12.29B EUR | 6.22B EUR | 8.37B EUR | 5.40B EUR | 5.56B EUR | 7.81B EUR |
| EPS | €1.83 | €1.50 | €1.73 | €1.14 | €4.91 | €2.49 | €3.19 | €2.15 | €2.19 | €3.20 |
| EPS (Diluted) | €1.83 | €3.36 | €1.73 | €1.14 | €4.91 | €2.49 | €3.18 | €2.15 | €2.19 | €3.20 |
| Shares Outstanding (Diluted) | 2,573.2 M | 2,513.8 M | 2,494.2 M | 2,499.8 M | 2,507.2 M | 2,505.0 M | 2,503.8 M | 2,512.8 M | 2,502.8 M | 2,440.8 M |
Price
| Price | $44.34 (closing price, October 30, 2026) |
| Market Cap | $106.9B |
| Exchange | NASDAQ |
| Country | FR |
Related companies: MRK · AMGN · GILD · LLY · AZN · NVS · NVO · PFE
Explore sector: Healthcare · Drug Manufacturers - General
More sections of SNY: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks